Clinical trials: Esomeprazole, completed
GERD Without Erosive Esophagitis
A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.
The primary objective is to compare the efficacy between three doses of AZD0865 (25, 50 and 75 mg). The secondary objectives are to compare the efficacy between the three doses of AZD0865 and esomeprazole 20 mg and to evaluate…
- Trial name
- NCT00206284
- Testing
- AZD0865
- Where
- 202 sites in United States, Canada and 8 more
- Volunteers
- 1,400 people
- Sponsor
- AstraZeneca
Solid Tumors, Lymphoma
Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib
The purpose of this study is to assess the drug-drug interaction (DDI) of either esomeprazole or rifampin on the single-dose PK of alisertib, and to complete an intensive QT study of single and multiple-dose alisertib.
- Trial name
- NCT01844583
- Testing
- Alisertib, Esomeprazole, Rifampin
- Where
- 7 sites in United States
- Volunteers
- 55 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Gastric Ulcer, Duodenal Ulcer
Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation
The purpose of this study is to confirm the safety profile / factors which impact safety and efficacy in patients given triple therapy for Helicobacter pylori eradication with Nexium + amoxicillin (AMPC) + clarithromycin (CAM)…
- Conditions
- Gastric Ulcer, Duodenal Ulcer, Gastric Mucosa-associated Lymphoid Tissue (MALT), Lymphoma Idiopathic Thrombocytopenic Purpura
- Trial name
- NCT01435525
- Where
- 36 sites in Japan
- Volunteers
- 369 people
- Sponsor
- AstraZeneca
Helicobacter Pylori Infection
Levofloxacin-containing Therapies In Second Line Helicobacter Pylori Eradication
Asia Pacific Consensus states that levofloxacin-based triple therapy as an alternative second-line therapy after Helicobacter pylori (H. pylori) eradication failure when bismuth salts are not available.
- Trial name
- NCT02596620
- Testing
- Nexium, Amolin, Cravit
- Volunteers
- 164 people
- Sponsor
- Chang Gung Memorial Hospital
Gastro-oesophageal Reflux
A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg
The primary objective of this study is to compare, the number of patients with heartburn and regurgitation symptom resolution after treatment with either rabeprazole 20 mg, esomeprazole 20 mg or esomeprazole 40 mg.
- Trial name
- NCT00464308
- Testing
- Esomeprazole, Rabeprazole
- Where
- 25 sites in Australia
- Volunteers
- 1,392 people
- Sponsor
- Janssen-Cilag Pty Ltd
GERD
Nexium RESPONSE Trial
The primary purpose of the study is to develop, and test, an algorithm for identification of responders to empirical esomeprazole treatment in general practices.
- Trial name
- NCT00318968
- Testing
- Esomeprazole
- Where
- 38 sites in Denmark
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Helicobacter Pylori Infection
Rescue Therapy for Helicobacter Pylori Eradication Treatment
Current guidelines have recommended classical bismuth-containing quadruple therapy including proton-pump inhibitor, bismuth, tetracycline, metronidazole as the empirical rescue therapy.
- Trial name
- NCT04531059
- Testing
- Esomeprazole, Bismuth Potassium Citrate, Tetracycline,Metronidazole
- Where
- 3 sites in China
- Volunteers
- 368 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Eosinophilic Esophagitis
Fluticasone Versus Esomeprazole to Treat Eosinophilic Esophagitis
The purpose of this study is to assess the clinical efficacy of proton pump inhibitors in comparison to aerosolized swallowed steroids for the treatment of eosinophilic esophagitis (EE).
- Trial name
- NCT00895817
- Testing
- Swallowed fluticasone, Esomeprazole
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Walter Reed Army Medical Center
Dyspepsia
Proton Pump Inhibitors Effects on Dyspepsia During Ramadan Fasting
evaluate the interest of proton pump inhibitors in subjects with or with GI symptoms who intend to observe fasting in Ramadan. The investigators will compare the effectiveness of proton pump inhibitors to prevent or reduce the…
- Trial name
- NCT05287633
- Testing
- Esomeprazole
- Where
- Tunisia
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of Monastir
Gastroesophageal Reflux
Which Supraesophageal Reflux Symptoms Reliably Respond to Proton-Pump-Inhibitor (PPI) Therapy
The investigators hypothesize that persons with the particular cluster of symptoms that are due to supraesophageal reflux (SER) will have complete resolution of those symptoms with adequate acid suppression when a PPI is…
- Trial name
- NCT00170001
- Testing
- Nexium, Sugar Pill
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Healthy
Drug-Drug Interaction Study of Esomeprazole (D961H) Capsule and Loxoprofen Tablet After Repeated Oral Administration in Japanese Males
The purpose of this study is to evaluate the pharmacokinetic profile of Esomeprazole (D961H) during repeated oral administration with and without co-administration of loxoprofen and the pharmacokinetic profile of loxoprofen…
- Trial name
- NCT00676117
- Testing
- Esomeprazole (D961H), Loxoprofen
- Where
- Japan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Esomeprazole Bioavailability Study With 40 mg Oral Single Dose Fasted and Fed Administration
The present study will be conducted in order to compare the bioavailability of 40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland) and of INexium 40 mg MUPS tablets (AstraZeneca, France) under single dose fasted and fed…
- Trial name
- NCT00889850
- Testing
- 40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland), INexium 40 mg MUPS tablets (AstraZeneca, France)
- Where
- Germany
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Mepha Ltd.
Colorectal Cancer
Preoperative Non-steroidal Anti-inflammatory Drugs(NSAID) to Colorectal Cancer Patients
The study is designed to evaluate effects of NSAIDs on immune activity inside and close to tumor tissue in patients with colorectal cancer.
- Trial name
- NCT00473980
- Testing
- Indomethacin, celecoxib, esomeprazole
- Where
- Sweden
- Volunteers
- 28 people
- Sponsor
- Göteborg University
Critically Ill Patients, Indication for Stress Ulcer Prophylaxis
Gastric pH in Critically Ill Patients
H2-receptor antagonists are the gold standard for stress ulcer prophylaxis in critically ill patients. Various studies demonstrated superiority of proton pump inhibitors over H2-receptor antagonists in increasing gastric pH and…
- Trial name
- NCT00590928
- Testing
- esomeprazole, ranitidine
- Where
- Austria
- Volunteers
- 75 people
- Sponsor
- Medical University of Vienna
Gastro-Oesophageal Reflux Disease
PPI Sequencing Study
The purpose of this study is to assess how patients with gastro-oesophageal reflux disease (heartburn) who are currently receiving treatment with a proton pump inhibitor but are still experiencing symptoms will benefit from a…
- Trial name
- NCT00384592
- Testing
- Esomeprazole, Physical exam, Pregnancy test if applicable
- Where
- 14 sites in United Kingdom
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Refractory Reflux Esophagitis
Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)
This is a phase 3 multicentre, randomised, double-blind, parallel-group, comparative study to evaluate the efficacy of esomeprazole (D961H) 20 mg twice daily and esomeprazole (D961H) 20 mg once daily in patients (in the form of…
- Trial name
- NCT01669811
- Testing
- Esomeprazole (D961H) twice daily, Esomeprazole (D961H) once daily
- Where
- 63 sites in Japan
- Volunteers
- 1,398 people
- Sponsor
- AstraZeneca
Non-erosive Reflux Disease
Diagnosis of Acid Reflux Disease Using Novel Imaging: A Prospective Study
Gastroesophageal reflux disease (GERD), a common chronic disorder in the veteran population, is associated with drug costs exceeding $ 10 billion/year. Only 30-40% of patients with reflux symptoms have erosive esophagitis.
- Trial name
- NCT02081404
- Testing
- Esomeprazole
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Midwest Biomedical Research
Reflux Esophagitis
Study to Investigate the Safety, Tolerability and Efficacy of YH4808 in Patients With Reflux Esophagitis
This study is to investigate the optimal clinical dose and administration methods of YH4808 in patients with reflux esophagitis by evaluating the safety and efficacy after YH4808 oral administration.
- Trial name
- NCT01538849
- Testing
- Esomeprazole 40mg, YH4808 A mg, YH4808 B mg
- Where
- South Korea
- Volunteers
- 154 people
- Sponsor
- Yuhan Corporation
Gastroesophageal Reflux
The Gastrointestinal Microbiome of Infants With GERD and PPI Therapy: a Pilot Study
Proton Pump Inhibitors (PPI) are standard in the therapy of pediatric GERD. In the past it has been hypothesized, that either direct inhibition of bacterial ATPase or elevation of the pH may lead to changes in the intestinal…
- Trial name
- NCT02359604
- Testing
- PPI therapy, Stool sample
- Where
- Austria
- Volunteers
- 12 people
- Sponsor
- Medical University of Graz
Hospitalized Cases of Angioneurotic Oedema, Pneumonia
Drug Utilization and Safety Events Among Children Using Esomeprazole, Other Proton Pump Inhibitors or H2-receptor Antagonists
The purpose of this study is 1. To describe patient characteristics and drug usage among children that are prescribed esomeprazole for the first time and to compare them with patients who are prescribed other proton pump…
- Conditions
- Hospitalized Cases of Angioneurotic Oedema, Pneumonia, Gastroenteritis, Failure to Thrive
- Trial name
- NCT01338363
- Where
- Netherlands
- Volunteers
- 23,470 people
- Sponsor
- AstraZeneca